Retatrutide is not yet FDA approved, but like many GLP-1 agonists such as Wegovy (semaglutide) and Mounjaro (tirzepatide), retatrutide will most likely be a weekly injection, delivered subcutaneously into the arm, thigh or stomach area in a self-inject pen
Get a comprehensive hormone panel If you have not had your sex hormones checked since starting GLP-1 therapy, request a full panel including total and free testosterone, estradiol, SHBG, LH, FSH, and thyroid function
The ad said eligible patients could get prescribed GLP-1s, the buzzy class of obesity treatments that's turned into a booming business in recent years
therefore, ages with higher cardiovascular mortality as a share of overall mortality are expected to see greater mortality reductions
Supplementary Table 4), with an average predicted reduction of 2.87 percentage points in BMI loss for people with a T2D diagnosis
Clinical trials and results Retatrutide is currently in phase 3 clinical trials for weight loss, but results from phase 2 trials are promising